Jump Financial LLC Sells 42,052 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Jump Financial LLC lowered its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 56.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,803 shares of the company's stock after selling 42,052 shares during the period. Jump Financial LLC's holdings in 10x Genomics were worth $1,780,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TXG. UMB Bank n.a. raised its holdings in shares of 10x Genomics by 51.6% in the 4th quarter. UMB Bank n.a. now owns 782 shares of the company's stock worth $44,000 after purchasing an additional 266 shares during the period. Harvest Fund Management Co. Ltd bought a new stake in shares of 10x Genomics in the fourth quarter valued at $66,000. Van ECK Associates Corp lifted its position in shares of 10x Genomics by 23.4% during the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company's stock valued at $107,000 after buying an additional 362 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of 10x Genomics during the 3rd quarter worth $146,000. Finally, Powell Investment Advisors LLC bought a new position in shares of 10x Genomics during the 4th quarter worth $200,000. Institutional investors own 84.68% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus dropped their price objective on shares of 10x Genomics from $63.00 to $53.00 and set a "buy" rating on the stock in a report on Wednesday, May 1st. TD Cowen lowered shares of 10x Genomics from a "buy" rating to a "hold" rating and lowered their price target for the company from $57.00 to $32.00 in a research report on Wednesday, May 1st. Bank of America cut their price objective on shares of 10x Genomics from $45.00 to $36.00 and set a "neutral" rating for the company in a report on Wednesday, May 1st. UBS Group reduced their price objective on shares of 10x Genomics from $52.00 to $30.00 and set a "neutral" rating for the company in a research note on Wednesday, May 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on 10x Genomics from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $48.50.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 2,821 shares of 10x Genomics stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $130,725.14. Following the completion of the sale, the chief executive officer now directly owns 847,560 shares of the company's stock, valued at approximately $39,275,930.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Serge Saxonov sold 2,821 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $130,725.14. Following the transaction, the chief executive officer now directly owns 847,560 shares in the company, valued at approximately $39,275,930.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 2,613 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $121,086.42. Following the completion of the sale, the insider now owns 283,059 shares of the company's stock, valued at approximately $13,116,954.06. The disclosure for this sale can be found here. Insiders have sold 11,959 shares of company stock valued at $543,276 over the last three months. 10.65% of the stock is owned by corporate insiders.

10x Genomics Trading Down 0.6 %

Shares of 10x Genomics stock traded down $0.17 during trading on Wednesday, hitting $26.39. The stock had a trading volume of 1,299,965 shares, compared to its average volume of 1,571,051. 10x Genomics, Inc. has a 12 month low of $24.60 and a 12 month high of $63.57. The firm has a market cap of $3.14 billion, a price-to-earnings ratio of -11.83 and a beta of 1.94. The business's 50-day moving average is $32.81 and its 200 day moving average is $41.41.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.50). The business had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.44) EPS. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.55 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.